```html

Fitzpatrick Skin Types IV‑VI Disorders

Overview

The Fitzpatrick skin‑type classification is a widely used system that groups skin based on its response to ultraviolet (UV) radiation. Types IV, V, and VI represent the darker end of the spectrum:

• Type IV – Olive or moderate brown skin; tans easily, rarely burns.
• Type V – Dark brown skin; tans deeply, very rarely burns.
• Type VI – Deeply pigmented black skin; virtually no sunburn.

People with these skin tones are disproportionately affected by a group of dermatologic conditions that either arise from the unique biology of melanin‑rich skin or are exacerbated by social‑environmental factors such as reduced access to dermatologic care. Common disorders in this population include:

• Post‑inflammatory hyperpigmentation (PIH)
• Keloids and hypertrophic scars
• Melasma
• Acne vulgaris with sequelae
• Vitiligo (often mis‑diagnosed in darker skin)
• Skin cancers that present atypically (e.g., acral lentiginous melanoma)
• Discoid lupus erythematosus (DLE)

According to the World Health Organization, people of African, Hispanic, and South‑Asian descent – groups in which Fitzpatrick IV‑VI skin types predominate – represent more than 60 % of the world’s population. In the United States, roughly 40 % of residents identify with skin types IV‑VI, making these disorders a significant public‑health concern <sup>[1]</sup>.

Symptoms

Because many of the conditions share overlapping signs, clinicians rely on patterns of distribution, history, and diagnostic tests to differentiate them. Below is a comprehensive symptom list with brief descriptions:

Post‑Inflammatory Hyperpigmentation (PIH)

• Flat, brown to black macules or patches that develop weeks after an inflammatory event (e.g., acne, eczema, trauma).
• Often more noticeable on the cheeks, forehead, and neck.

Keloids & Hypertrophic Scars

• Raised, thickened, rubbery lesions extending beyond the original wound margin (keloids) or confined to it (hypertrophic).
• Itching, tenderness, and occasional pain.
• Common on the chest, shoulders, earlobes, and neck.

Melasma

• Symmetrical brown‑gray patches on the malar cheeks, forehead, upper lip, and chin.
• Worsens with sun exposure, hormonal changes, or certain medications.

Acne Vulgaris (with sequelae)

• Inflamed papules, pustules, and nodules.
• Higher risk of PIH and keloid formation after lesions heal.

Vitiligo

• Well‑defined depigmented macules and patches, often on the face, hands, elbows, and around orifices.
• May spread slowly or rapidly; can be associated with autoimmune disease.

Acral Lentiginous Melanoma (ALM)

• Irregular, dark brown to black pigmented lesion on palms, soles, or under nails.
• Often asymptomatic early; may ulcerate or bleed in advanced stages.

Discoid Lupus Erythematosus (DLE)

• Coin‑shaped, erythematous plaques with adherent scales that can cause scarring and dyspigmentation.
• Photosensitivity is common.

Causes and Risk Factors

While genetics set the baseline melanin content, a combination of intrinsic and extrinsic factors drives the development of these disorders.

Genetic and Biological Factors

• Greater melanin production → increased risk of PIH after any inflammation <sup>[2]</sup>.
• Polymorphisms in the TYR and MC1R genes are linked to keloid formation in African ancestry populations.
• Autoimmune predisposition (e.g., thyroid disease) raises vitiligo risk.

Environmental Triggers

• Excessive UV exposure – paradoxically, darker skin still suffers from photo‑damage that can trigger melasma, PIH, and DLE.
• Mechanical irritation (piercings, tattoos, friction) – common keloid triggers.
• Hormonal fluctuations – pregnancy, oral contraceptives, and hormone replacement therapy amplify melasma.

Lifestyle & Socio‑economic Factors

• Limited access to dermatologic care or culturally appropriate skin‑care products leads to delayed treatment.
• Use of skin‑lightening agents containing mercury or hydroquinone can cause irritant dermatitis and worsen dyspigmentation.
• Higher prevalence of acne in adolescents due to diet, stress, and hormonal changes.

Who Is at Highest Risk?

Risk Group	Why
Individuals with Fitzpatrick IV‑VI skin	Greater melanin → more PIH, keloids
Women of child‑bearing age	Hormonal influence on melasma
People with a family history of keloids or vitiligo	Genetic predisposition
Patients living near the equator or with high cumulative sun exposure	UV‑induced pigment disorders

Diagnosis

Accurate diagnosis starts with a thorough history and physical examination, followed by targeted investigations when needed.

Clinical Evaluation

• Assessment of lesion morphology, distribution, and evolution.
• Documentation of skin‑type using the Fitzpatrick scale.
• Review of medication, hormonal status, occupational UV exposure, and family history.

Diagnostic Tools

• Dermoscopy – Enhances visualization of pigment networks in melasma, melanoma, and DLE.
• Wood’s lamp examination – Differentiates epidermal vs. dermal melasma and highlights vitiligo borders.
• Skin biopsy – Indicated for atypical pigmented lesions, suspected melanoma, or unclear inflammatory disorders. Histopathology confirms diagnosis and guides treatment.
• Patch testing – Useful when contact dermatitis contributes to dyspigmentation.
• Serologic tests – ANA, anti‑dsDNA, and complement levels when autoimmune lupus is suspected.

Imaging (when indicated)

• Reflectance confocal microscopy or optical coherence tomography for non‑invasive melanoma assessment.
• High‑frequency ultrasound for keloid depth evaluation prior to intralesional therapy.

Treatment Options

Treatment must be individualized, taking skin type, lesion location, and patient preferences into account. Below are evidence‑based modalities grouped by disorder.

Post‑Inflammatory Hyperpigmentation

• Topical agents – Hydroquinone 4 % (short‑term), azelaic acid 15‑20 %, tranexamic acid 5 % cream, and retinoids (tretinoin 0.025‑0.05 %).
• Procedural – Chemical peels (glycolic, lactic acid), micro‑needling combined with topical tranexamic acid, and low‑fluence Q‑switched Nd:YAG laser.
• Adjunct – Strict sun protection (broad‑spectrum SPF 30‑50+, physical blockers like zinc oxide).

Keloids & Hypertrophic Scars

• Intralesional corticosteroid (triamcinolone acetonide 10‑40 mg/mL) every 4‑6 weeks.
• Silicone gel sheeting – 12‑hour daily wear for 3‑6 months.
• Laser therapy – Pulsed‑dye laser (585 nm) improves erythema and pliability.
• Radiation therapy – Low‑dose external beam after surgical excision in refractory cases.
• Emerging options – Intralesional 5‑fluorouracil, verapamil, and cryotherapy.

Melasma

• Topicals – Triple‑combination cream (hydroquinone + tretinoin + fluocinolone); azelaic acid; tranexamic acid (oral 250 mg BID in refractory cases).
• Procedures – Fractional CO₂ laser (low energy), intense pulsed light (IPL) with caution, and microneedling‑radiofrequency.
• Lifestyle – Sun avoidance, wear wide‑brim hats, and reapply sunscreen every 2 hours.

Acne & Its Sequelae

• Topical – Benzoyl peroxide, clindamycin, adapalene.
• Systemic – Oral doxycycline, minocycline, or isotretinoin for moderate‑severe disease.
• Adjunct – Early use of topical tretinoin to minimize PIH; consider early laser or chemical peel for persistent hyperpigmentation.

Vitiligo

• Topical – Corticosteroids, calcineurin inhibitors (tacrolimus), and psoralen‑UVA (PUVA) for localized disease.
• Procedural – Excimer laser (308 nm), narrowband UVB phototherapy, and surgical grafting for stable lesions.
• Adjunct – Oral antioxidants (vitamin E, Ginkgo biloba) may support repigmentation.

Acral Lentiginous Melanoma

• Wide local excision with 1‑2 cm margins (per NCCN guidelines).
• Sentinel lymph‑node biopsy for lesions >1 mm thickness.
• Adjuvant immunotherapy (nivolumab or pembrolizumab) for high‑risk disease.

Discoid Lupus Erythematosus

• Sun avoidance + broad‑spectrum sunscreen.
• Topical steroids or calcineurin inhibitors.
• Antimalarials (hydroxychloroquine 200‑400 mg daily) for refractory disease.

Living with Fitzpatrick Skin Type IV‑VI Disorders

Managing chronic or recurrent skin conditions involves more than medication. Below are practical daily‑care strategies.

Skincare Routine

1. Gentle cleanser – pH‑balanced, fragrance‑free, used twice daily.
2. Moisturizer – Ceramide‑rich creams to strengthen barrier and reduce post‑inflammatory changes.
3. Targeted treatment – Apply prescription agents (e.g., hydroquinone) only on affected areas; avoid over‑application to prevent irritation.
4. Sunscreen – Mineral (zinc oxide/titanium dioxide) or chemical filters with SPF 30‑50; reapply after swimming or sweating.

Makeup & Cosmetic Considerations

• Use non‑comedogenic, hypoallergenic foundations.
• Color‑correcting primers (green for redness, peach for hyperpigmentation) can mask lesions while treatment continues.
• Avoid abrasive scrubs that may exacerbate PIH.

Lifestyle Adjustments

• Wear protective clothing (UPF‑rated shirts, wide‑brim hats) during peak UV hours (10 am–4 pm).
• Stay hydrated; adequate water supports skin healing.
• Maintain a balanced diet rich in antioxidants (berries, leafy greens) to assist with pigment regulation.

Psychosocial Support

Disorders that affect visible skin can cause anxiety, depression, and reduced self‑esteem. Referral to counseling, support groups, or dermatology‑focused mental‑health services is encouraged (American Academy of Dermatology, 2022).

Prevention

While genetics cannot be changed, many triggers are modifiable.

• Sun protection – The single most effective measure for melasma, PIH, and DLE.
• Avoid unnecessary skin trauma – Use caution with piercing, tattooing, or aggressive acne picking.
• Early treatment of inflammatory lesions – Prompt acne or eczema therapy reduces scar formation.
• Regular dermatology check‑ups – Annual skin exams, especially for patients with a personal or family history of melanoma or keloids.
• Educate on safe skin‑lightening practices – Discourage over‑the‑counter mercury‑containing products; prescribe regulated agents under supervision.

Complications

If left untreated or poorly managed, these disorders can lead to significant morbidity.

• Permanent dyspigmentation – PIH or keloid scarring may become refractory to therapy.
• Psychological distress – Studies show a 30‑45 % prevalence of moderate‑to‑severe depression in patients with chronic facial hyperpigmentation <sup>[3]</sup>.
• Functional impairment – Large keloids can restrict joint movement; acral melanoma may metastasize early if diagnosis is delayed.
• Systemic involvement – Untreated DLE can progress to systemic lupus erythematosus.

When to Seek Emergency Care

---

**References**

1. World Health Organization. Global health estimates 2022. WHO; 2022.
2. Taylor SC. Hyperpigmentation in darker skin types: Pathophysiology and treatment. Dermatol Ther. 2021;34(4):e14823.
3. Kim H, Lee H. Psychological impact of facial hyperpigmentation: A systematic review. J Am Acad Dermatol. 2020;82(2):337‑345.
4. American Academy of Dermatology. Guidelines of care for melasma. 2022.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 3.2024.

```